Microbiotica announces the appointment of Dr Robert Tansley as Chief Medical Officer
Cambridge, UK – 10 June 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect.
Dr Tansley steps into the role at a key development stage for Microbiotica with its two lead programmes progressing through Phase 1 clinical trials in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis) with data read-outs anticipated this year.